Those are among the largest reductions reported for any medication in this class to date which is exactly why retatrutide is being watched so closely
Insurance coverage decisions typically require demonstration of obesity through BMI thresholds with or without metabolic comorbidities but do not specifically require established cardiovascular disease
"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial." Lancet, 400(10366), 1869-1881
Lynch L, Hogan AE, Duquette D, Lester C, Banks A, LeClair K, et al
Given the commercial scale of the obesity market, AstraZeneca is one of several large pharma players betting that the oral delivery format will be the dominant paradigm within a decade
However, adding too much water creates very dilute solutions that may be harder to work with, while too little water creates very concentrated solutions that require precise measurement
